Increased arterial stiffness in stable and severe asthma  by Sun, Wen-xue et al.
Respiratory Medicine (2014) 108, 57e62Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/rmedIncreased arterial stiffness in stable
and severe asthma*Wen-xue Sun a, Di Jin b, Ying Li b,c, Rui-tao Wang b,*aDepartment of Respiratory, The First Affiliated Hospital, Harbin Medical University, Harbin,
Heilongjiang, China
bDepartment of Geriatrics, The Second Affiliated Hospital, Harbin Medical University, Harbin,
Heilongjiang, China
c International Physical Examination and Healthy Center, The Second Affiliated Hospital,
Harbin Medical University, Harbin, Heilongjiang, ChinaReceived 17 August 2013; accepted 27 October 2013
Available online 5 November 2013KEYWORDS
Asthma;
Brachial-ankle pulse
wave velocity;
Pulmonary function;
Arterial stiffness;
High sensitivity C-
reactive protein* WX.S participated in data collectio
participated in manuscript preparatio
thors read and approved the final ma
* Corresponding author. Department
District, Harbin 150086, China. Tel.: þ
E-mail address: ruitaowang@126.c
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.201Summary
Background: Systemic inflammation is related to disease progression in asthma. The brachial-
ankle pulse wave velocity (baPWV) is a marker for early atherosclerotic changes. The aim of
this study is to evaluate the baPWV levels in patients with stable and severe asthma.
Methods: We examined baPWV, high sensitivity C-reactive protein (CRP), lung function param-
eters, and arterial blood gas analysis in patients with asthma and control subjects. 85 stable
asthma patients and 85 severe asthmatics were investigated. 85 control subjects matched
for age, gender, body mass index (BMI) and smoking status were recruited.
Results: The patients with severe asthma had increased baPWV and CRP compared with the
patients with stable asthma and control subjects. Furthermore, baPWV was elevated in stable
asthma compared with control subjects. There was a negative correlation between baPWV and
forced expiratory volume in 1 s (FEV1), after adjusting age, gender, BMI and smoking status
(r Z 0.414, p < 0.001). Similarly, baPWV was negatively correlated with FEV1/forced vital
capacity (FVC) (r Z 0.431, p < 0.001). Although there was no correlation between CRP
and baPWV in patients with stable asthma, CRP was positively correlated with baPWV in pa-
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58 W.-xue Sun et al.Conclusions: baPWV tends to increase as pathogenic condition aggravated in asthma. In addi-
tion, elevated baPWV correlates with impaired lung function. Our observation suggests that
baPWV is useful for early detection of subclinical atherosclerosis in asthma.
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Asthma is anenormous public health problem inUSA resulting
in considerable burden and cost. Substantial evidence
demonstrated asthma is a chronic inflammatory condition
with activation of large numbers of immune and inflamma-
tory cells within the airways. Recent studies reported that
systemic inflammation is related to disease progression in
asthma [1]. Some proinflammatory cytokines such as inter-
leukin 6 (IL-6), tumor necrosis factora (TNFa), andC reactive
protein (CRP) are elevated in patients with asthma [1e3].
Elevated arterial stiffness, a marker of subclinical
atherosclerosis, is associated with myocardial infarction,
heart failure, stroke, renal disease, and elevated total
mortality [4]. Pulse wave velocity (PWV) reflects the stiff-
ness of central and peripheral muscular arteries and is
widely used as an indicator of arterial stiffness and vascular
damage. Brachial-ankle PWV (baPWV) measurement, a
simple, noninvasive, and automated measurement method,
is closely correlated with aortic PWV. Previous studies
documented that increased baPWV is linked with metabolic
syndrome, cardiovascular diseases, stroke, and renal dis-
ease, as well as elevated total mortality [5e8].
Mounting evidence revealed that the patients with
asthma are at increased risks of hypertension, pulmonary
embolism, coronary heart disease, heart failure, and all-
cause mortality [9e12]. However, the changes of baPWV
levels in asthma have not been clearly determined.
The purpose of the present study is to evaluate baPWV
levels in stable and severe asthma.
Methods
Participants
The study enrolled 255 adults (aged >18 years, 114 men and
141 women) from June 2011 to June 2012. There were 170
patients with asthma and 85 controls without asthma. The
severe asthma patients were included consecutively in the
department of respiratory, the First Affiliated Hospital. The
stable asthma patients and controls were recruited from the
International Physical Examination and Healthy Center of the
Second Affiliated Hospital. Control subjects were matched for
age, gender, and body mass index (BMI), and smoking status.
The study protocol was approved by the Ethics Committee of
the First and Second Hospital of Harbin Medical University,
China. Written informed consent was obtained from study
participants.
Clinical examination
All the subjects underwent clinical examination which
included anthropometric and blood pressure measurements.Bodymass index (BMI)was calculated asweight (kg) dividedby
height (m2). Blood pressure was determined using a mercury-
gravity sphygmomanometer in a sitting position after a 15-min
resting period. Systolic and diastolic blood pressures were
measured twiceonthe samedayandmeanvalueswereused in
the analysis.
Biochemical measurements
Clinical data including smoking habits, medical history and
medication use were recorded for each subject. The whole
blood samples were drawn in EDTA-containing tubes after
an 8-h overnight fasting and all samples were processed
within 30 min after blood collection with an autoanalyzer
(Sysmex XE-2100, Kobe, Japan). High sensitivity C-reactive
protein (CRP) was measured by the nephelometric method
(Dade Behring, Marburg, Germany). An arterial blood sam-
ple was assayed with a blood gas analyzer (GEM premier
3000, MA, USA) while the subjects were breathing room air
for at least 30 min. Forced expiratory volume in one second
(FEV1) was determined with a spirometer (Jaeger, Wurz-
burg, Germany) according to the American Thoracic Society
criteria. Spirometric measurements were analyzed three
times and the best result was used in our study. The inter-
and intra-assays coefficients of variation (CVs) of all these
assays were below 5%.
Measurement of baPWV
BaPWV was measured using an automatic device (model
MB3000, M&B Electronic Instruments, Beijing, China). The
baPWV was automatically calculated according to the for-
mula (L/PTT). L is the difference between the length from
the heart to ankle and the length from the heart to
brachium. PTT was the pulse transit time between the
brachial and tibial arterial waveforms. All measurements
were conducted by a single examiner who was blinded to
the clinical data. The method was validated in a previous
report [13].
Diagnosis and exclusion criteria
Stable and severe asthma was defined according to Global
Initiative Strategy for Asthma Management (GINA) guide-
lines. Exclusion criteria were chronic lung disease other than
asthma, coronary heart disease, systemic inflammatory dis-
eases, heart failure, renal failure, and medical treatment
with statins, angiotensin converting enzyme inhibitors, and
systemic glucocorticoids during the previous 8 weeks.
Statistical analysis
Data were expressed as means  SD or median (inter-
quartile range) for continuous variables or percentage for
Table 2 Partial correlation of baPWV with laboratory
parameters after adjustment for age, gender, BMI and
smoking status.
Variables baPWV (cm/s)
r p-Value
Whole group (asthma D controls)
CRP (mg/L) 0.375 <0.001
FEV1 (% predicted) 0.414 <0.001
FEV1/FVC (%) 0.431 <0.001
Severe asthma group
CRP (mg/L) 0.229 0.039
FEV1 (% predicted) 0.277 0.012
FEV1/FVC (%) 0.204 0.067
Stable asthma group
CRP (mg/L) 0.117 0.298
FEV1 (% predicted) 0.153 0.174
FEV1/FVC (%) 0.237 0.033
BaPWV, brachial-ankle pulse wave velocity; CRP, high sensitivity
C-reactive protein; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity. CRP was log-transformed for analysis.
baPWV is elevated in asthma 59categorical variables. Group comparisons were conducted
using ANOVA test for normally distributed data, Krus-
kaleWallis test for non-parametric data and chi-square test
for categorical data. Post hoc analyses using two-tailed
Tukey’s HSD were conducted to compare the differences
for normally distributed data between the groups. Man-
neWhitney U test was used to compare the differences for
non-parametric data between the groups. Correlations be-
tween baPWV and clinical parameters were tested by par-
tial correlation with age, BMI, and smoking as continuous
variables and gender as dichotomous variables. CRP was
skewed and was normalized by logarithmic transformation.
Differences and correlations were considered significant at
P < 0.05 and all reported P values are two tailed. Statistical
analyses were conducted with SPSS version 17.0 software
(SPSS Inc., Chicago, IL, USA).
Results
The clinical characteristics of subjects are presented in
Table 1. The groups were well-matched with respect to
age, gender, BMI and smoking status. The medication with
inhaled corticosteroid was more prevalent in asthma group.
Significant differences in pulmonary function parameters
(FEV1 and FEV1/forced vital capacity (FVC)) were observed
between the groups. The patients with severe asthma had
increased baPWV and CRP compared to the patients with
stable asthma and control subjects. Furthermore, baPWV
was elevated in stable asthma compared with control
subjects.
The partial correlation coefficients of baPWV with lab-
oratory parameters after adjustment for age, gender, BMITable 1 Clinical and laboratory characteristics in severe and st
Variables Severe asthma
Number 85
Age (years) 40.6 (4.0)
Gender (male, %) 42 (49)
BMI (kg/m2) 24.9 (3.0)
Smoker (%)
Current smoker 12(14)
Ex-smoker 16 (19)
Non-smoker 57(67)
SBP (mmHg) 125.5 (9.5)
DBP (mmHg) 70.1 (5.4)
Medication
Inhaled Corticosteroids (%) 61 (72)
FEV1 (% predicted) 63.9 (11.4)
FEV1/FVC (%) 54.1 (10.6)
PaO2 (mmHg) 67.4 (8.6)
PaCO2 (mmHg) 31.6 (5.9)
Haemoglobin (g/dl) 129.9 (13.3)
CRP (mg/L) 11.8 (8.7e17.8)
BaPWV (cm/s) 1384.2 (111.6)
Data are presented as means (SD) or median (interquartile range) or
DBP, diastolic blood pressure; FEV1, forced expiratory volume in 1 s; F
baPWV: brachial-ankle pulse wave velocity. p-Value was calculated by
*p-Value was obtained by comparison of severe and stable asthma usand smoking status are reported in Table 2. There was a
negative correlation between baPWV and FEV1, after
adjusting age, gender, BMI and smoking status (rZ 0.414,
p < 0.001) (Fig. 1). Similarly, there was a negative corre-
lation between baPWV and FEV1/FVC, after adjusting age,
gender, BMI and smoking status (r Z 0.431, p < 0.001)
(Fig. 2). Further analysis showed that baPWV was nega-
tively correlated with FEV1 in severe asthma and baPWVable asthma patients and control subjects.
Stable asthma Controls p-Value
85 85
39.8 (4.0) 40.5 (4.4) 0.109
35 (41) 37 (44) 0.539
25.3 (3.2) 25.2 (2.3) 0.436
15 (18) 16 (19) 0.695
21 (14) 18 (21) 0.644
49 (58) 51 (60) 0.422
123.9 (6.6) 124.6 (7.5) 0.162
71.2 (5.9) 69.7 (5.5) 0.395
36 (42) 0 <0.001*
77.5 (17.5) 94.4 (6.8) <0.001
71.4 (7.4) 83.9 (7.5) <0.001
81.6 (7.7) 87.5 (9.3) <0.001
35.3 (8.3) 39.1 (4.4) <0.001
132.7 (10.7) 132.7 (12.2) 0.147
8.2 (5.5e11.3) 2.5 (1.9e3.4) <0.001
1364.0 (131.6) 1226.2 (120.3) <0.001
percentage. BMI, body mass index; SBP, systolic blood pressure;
VC, forced vital capacity; CRP, high sensitivity C-reactive protein;
one-way ANOVA test or KruskaleWallis H test or chi-square test.
ing chi-square test.
Figure 1 The partial correlation coefficient of baPWV with FEV1% is presented in Fig. 1 after adjusting for age, gender, BMI and
smoking status. BaPWV is negatively correlated with FEV1%.
60 W.-xue Sun et al.was negatively correlated with FEV1/FVC in stable asthma.
Although there was no correlation between CRP and baPWV
in patients with stable asthma, CRP was positively corre-
lated with baPWV in patients with severe asthma
(r Z 0.229, p Z 0.039).Figure 2 The partial correlation coefficient of baPWV with FEV1
and smoking status. BaPWV is negatively correlated with FEV1/FVCA two-sided Pearson chi-square test was used to analyze
the baPWV levels as a correlate of control subjects, stable
asthmatics, and severe asthmatics (see Table 3). The re-
sults showed a significant difference of baPWV levels in
different groups (for the control group vs. stable asthma/FVC is presented in Fig. 2 after adjusting for age, gender, BMI
.
Table 3 The analyzed participants distributed according
to baPWV quartiles.
Q1 Q2 Q3 Q4
BaPWV (cm/s) 1212 1213e1301 1302e1412 1413
Control (n) 57 15 5 8
Stable asthma (n)* 5 31 35 14
ySevere asthma (n)* 2 22 20 41
Total (n) 64 68 60 63
BaPWV, brachial-ankle pulse wave velocity. *P < 0.001
compared with the control group; yP < 0.001 when stable
asthma group compared with severe asthma group.
baPWV is elevated in asthma 61group, c2 Z 73.3, P < 0.001; for the control group vs. se-
vere asthma group, c2Z 83.8, P < 0.001; for stable asthma
group vs. severe asthma group, c2 Z 20.2, P < 0.001).
Discussion
The main findings of our study are the following: asthmatics
had increased baPWV compared to the controls. BaPWV
negatively correlated with lung function. Moreover,
elevated baPWV was positively related to CRP levels in
severe asthma.
There are increased risks of hypertension, pulmonary
embolism, coronary heart disease, heart failure, stroke,
and all-cause mortality for patients with asthma [9e12].
Systemic inflammation may be the main mechanism for the
development and progression of atherosclerosis in asthma.
Some proinflammatory cytokines such as interleukin 6 (IL-
6), tumor necrosis factor a (TNFa), and C reactive protein
(CRP) are elevated in patients with asthma [3]. Multifac-
torial complex interactions between platelets, endothelial
cells and leukocytes further stimulate production of
proinflammatory cytokines and accelerate progression of
atherosclerosis [14]. In addition, increased circulating
platelet-leukocyte aggregates have been detected in pa-
tients with asthma attacks. Recently, a study demonstrated
that acute inflammation may cause a significant increase in
arterial stiffness [15]. Therefore, evaluating cardiovascular
disease risk in asthmatics applying reliable disease markers
is of great clinical significance.
Arterial stiffness is a strong predictor of future cardio-
vascular events and all-cause mortality [16]. The associa-
tion between increased arterial stiffness and reduced lung
volumes has been recently documented [17]. Systemic
inflammation mediates the association between lower lung
function and cardiovascular disease [18,19]. Our result
showed that increased baPWV is positively correlated with
CRP only in severe asthma not in stable asthma. These
findings are consistent with the idea that the intensity of
systemic inflammation rises in severe asthma.
Our result showed that elevated baPWV is negatively
correlated with lung function. FEV1% is a generally
accepted surrogate marker of asthma severity. Lower lung
function is associated heart failure, stroke, and cardiovas-
cular death [20e22]. Furthermore, reduced FEV1 is a
stronger index of cardiovascular risk than traditional fac-
tors such as blood cholesterol [23]. This finding may bepartly account for the underlying mechanism linking asthma
with increased risk of cardiovascular events.
Age, gender, obesity and cigarette smoking exerted
positive effects on baPWV and weight loss and smoking
cessation reduced baPWV levels [24e27]. Therefore, we
selected the matched patients and ruled out the influence
of age, gender, and BMI, and smoking status in our study.
Previous studies have reported that the small arteries
elasticity index and systemic vascular resistance are tightly
correlated with FEV1 in asthma [28]. Furthermore,
increased carotid atherosclerosis was observed in adult-
onset asthma [29]. Our study indirectly confirmed the re-
sults using a simple index of atherosclerosis in asthma.
Moreover, our study revealed that increased baPWV is
positively related to CRP in severe asthma. Consistent with
our results, a recent study revealed that reduced lung
function is associated with systemic inflammation [18].
Further investigations into the role of baPWV in asthma may
be beneficial in the search for therapeutic targets.
The interpretation of this study has some limitations.
First of all, our study is a cross-sectional study, so we were
unable to infer causality. A prospective study is needed to
elucidate the exact association. Secondly, the study is
lacking information about the genetic contributions to
asthma [30].
Conclusions
Our study shows that baPWV tends to increase as patho-
genic condition aggravated in asthma. In addition, elevated
baPWV correlates with impaired lung function. Our obser-
vation suggests that baPWV is useful for early detection of
subclinical atherosclerosis in asthma.
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